Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: IL6 and YKL-40 (also known as chitinase 3-like 1 protein, CHI3L1) are produced by pancreatic cancer cells and macrophages and activate inflammation. C-reactive protein (CRP) is synthesized mainly in hepatic cells and primarily stimulated by IL6. The aim of this study was to determine the prognostic value of combined detection of serum IL6, YKL-40, and CRP in patients with pancreatic cancer receiving palliative chemotherapy.

METHODS: In all, 592 patients with unresectable pancreatic cancer from five hospitals in Denmark were included in the BIOPAC biomarker study between 2008 and 2017. Pretreatment and longitudinal serum values of IL6 and YKL-40 were determined. Baseline CRP and CA19-9 values were available for the whole cohort. Patients were dichotomized as low versus high using cutoffs for IL6 of >4.92 pg/mL, YKL-40 of >95% age-corrected percentile, and CRP of >10 mg/L. The main outcome was overall survival.

RESULTS: Combined elevations of serum IL6, YKL-40, and CRP were associated with worse survival in contrast to an isolated high concentration of a single marker. Serum IL6, YKL-40, and CRP were higher in patients with advanced stage disease and in patients with poor performance status. Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival.

CONCLUSIONS: Combined high baseline serum levels of IL6, YKL-40, and CRP are associated with poor survival.

IMPACT: Assessment of systemic inflammation via measurements of IL6, YKL-40, and CRP may be important for pancreatic cancer prognostication.

Original languageEnglish
JournalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Volume29
Issue number1
Pages (from-to)176-184
ISSN1055-9965
DOIs
Publication statusPublished - 2020

Bibliographical note

©2019 American Association for Cancer Research.

ID: 58587706